Everything Happening in Utah Life Sciences
Taking place on March 12, 2026, at the Hilton Salt Lake City Center, the competition provides early-stage healthcare companies with a premier platform to showcase innovations to experienced investors and industry leaders.
Check out the photo gallery from the 2026 JP Morgan Healthcare conference in San Francisco.
The purchase is expected to expand Haemonetics’ impact in fast-growing markets for structural heart and endovascular procedures.
State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026
DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease
Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions.
Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment
Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platform.
Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing
As we look back at 2025, we’re thankful for the progress our team and partners helped drive this year.
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
2025 marked a year of significant progress of reached milestones and successes for Bloom Surgical
A microbiologist, Adam Barker, PhD, was ARUP’s chief scientific officer and director of Research and Development before being named chief operations officer—now adds Reference Business Unit president to his title.
The Australian patent represents the first patent granted for the Company’s new point-of-care testing platform.
Merit Medical’s Fred Lampropoulos Honored by Nasdaq
Perimeter Solutions Announces Agreement to Acquire MMT for $685 Million
Freyya Recognized at Transatlantic Angel Competition (TAAC8)
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Collaboration expands Owlet’s national DME footprint, strengthens access for Medicaid and TRICARE families, and supports continued growth in prescription-backed revenue channel.
In-vitro studies confirmed strong uptake of cell-targeting nanoparticles by cancer cells and strong activation of Smart mRNAs inside cancer cells
Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas
Investors Buy up Stocks in Biggest Follow-on Offering Day in Biotech History
Talent Ready Utah Calling for Innovator Input
TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription marks first international expansion of the Company’s recurring-revenue platform.
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12).
New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement.
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8.
Prestigious recognition validates Canary Speech’s leadership in healthcare-focused AI voice technology and its proven interoperability with the Microsoft Cloud
bioMérieux Celebrates New Regional Headquarters in Riyadh, Saudi Arabia
PolarityBio thanks the clinical trial sites and, most importantly, the participants, for making this milestone in DFU biologic therapy development possible
Milestone enables immediate production of SiN/PEEK custom devices